Skip to content

Omeros OMER Additional Paid-In Capital

Additional Paid-In Capital at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1B+3.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.38B+19.6%
Immunome logo
ImmunomeIMNM
$1.37B+58.5%
Vor Biopharma logo
Vor BiopharmaVOR
$1.22B+120%
Annexon logo
AnnexonANNX
$1.17B+15.6%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.58B+197%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's additional paid-in capital?
Omeros (OMER) reported additional paid-in capital of $793.58M in Q1 2026.
How has Omeros's additional paid-in capital changed year-over-year?
Omeros's additional paid-in capital increased by 8.8% year-over-year, from $729.67M to $793.58M.
What is the long-term trend for Omeros's additional paid-in capital?
Over 5 years (2020 to 2025), Omeros's additional paid-in capital has grown at a 1.1% compound annual growth rate (CAGR), from $751.3M to $791.75M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.